Because positive SGLT-2 expression was not found in PDAC samples, we investigated the association between the expression level of SGLT-1 and clinicopathological characteristics, including age (< 64 and ≥ 64 years old), sex (female and male), lymph node metastasis (< 1, ≤1 and < 4, and ≥ 4), tumour size (≤4 cm and > 4 cm), TNM stage (I–II and III), tumour pathological grade (I–II, III and IV), SMA/SMV invasion (yes and no), and diabetes history (yes and no). This evidence concerns the gene SLC5A2 and metastatic malignant neoplasm in the lymph nodes.